Clover Health NEOs Miss 2025 Bonuses, Executive Chair Forfeits 12.7M PRSUs Amid Performance Shortfalls
CLOV sits 65% above its 52-week low of $1.58.
Summary
Clover Health's 2025 executive compensation was severely impacted by unmet performance targets, leading to no annual bonuses for NEOs and a significant forfeiture of performance-based equity for the Executive Chairperson.
Key Events · Corporate Governance and Compliance · CLOV
-
Executive Compensation Targets Missed
Named Executive Officers (NEOs) received no annual bonuses for 2025 and no payout for the first tranche of the 2025 long-term incentive plan due to the company not meeting performance thresholds for Adjusted EBITDA and Stars rating.
-
Executive Chairperson Forfeits Substantial Equity
Executive Chairperson Vivek Garipalli forfeited 12,735,745 hybrid performance-based restricted stock units (PRSUs) as of January 7, 2026, because the company's stock price milestones were not achieved within the five-year performance period.
-
CEO's Compensation Actually Paid Turns Negative
For 2025, CEO Andrew Toy's 'Compensation Actually Paid' (CAP) was negative $3,076,416, primarily reflecting a decline in the fair value of his equity awards due to the company's stock performance.
-
New Related-Party Agreement with Warrants
Clover Care Services entered into an agreement with GoldenScript, Inc., an entity in which Executive Chairman Vivek Garipalli has a 25% indirect interest. The arrangement includes medication therapy management and pharmacogenomic services, with Clover Health receiving warrants to purchase approximately 910,600 shares of GoldenScript common stock at an exercise price of $0.01 per share.
Analysis · CLOV · Finance
This definitive proxy statement reveals significant underperformance by Clover Health against its 2025 financial and operational targets, directly impacting executive compensation. The failure to achieve performance metrics resulted in no annual bonuses for Named Executive Officers (NEOs) and no payout for the first tranche of the 2025 long-term incentive plan. Most notably, Executive Chairperson Vivek Garipalli forfeited over 12.7 million performance-based restricted stock units (PRSUs) due to unmet stock price milestones, a substantial loss reflecting poor stock performance. Additionally, CEO Andrew Toy's 'Compensation Actually Paid' for 2025 was negative, further highlighting the impact of declining equity value. These compensation outcomes, coupled with the previously reported worsening financial baseline, signal ongoing operational challenges and a failure to meet internal growth and profitability goals. Investors should view these disclosures as a strong negative indicator of the company's recent performance and the effectiveness of its strategic initiatives.
At the time of this filing, CLOV was trading at $2.61 on NASDAQ in the Finance sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $1.58 to $3.92. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.